KATERZIA

PeakSM

amlodipine

NDAORALSUSPENSION
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

(calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac…

Clinical Trials (5)

NCT06236061Phase 3Completed

Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

Started Apr 2024
718 enrolled
Hypertension
NCT03205137N/AWithdrawn

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

Started Jun 2022
0
Hypertension
NCT06713785Phase 4Withdrawn

Personalised Electronic Record Supported Optimisation of Amlodipine for Patients With Hypertension

Started Sep 2020
NCT03226275Phase 1Completed

Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese Participants

Started Aug 2017
32 enrolled
Healthy
NCT02969265Phase 3Withdrawn

An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension

Started May 2017
0
Hypertension

Loss of Exclusivity

LOE Date
Apr 11, 2039
159 months away
Patent Expiry
Apr 11, 2039

Patent Records (5)

Patent #ExpiryTypeUse Code
12383498
Oct 6, 2037
Product
12053461
Oct 6, 2037
Product
12336984
Oct 6, 2037
U-3448
10894039
Oct 6, 2037
U-185
10952998
Oct 6, 2037
Product